Virica Biotech And Fujifilm Biosciences Collaborate Under The Canada-japan Co-innovation Program To Advance Aav Production Enhancers

Virica Biotech ("Virica"), a compartment enhancer institution specializing successful Viral Sensitizers (VSE™) for viral vector manufacturing, coming announced it is receiving advisory services and backing from nan National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), nether nan Canada-Japan Corporate Co-Innovation Program for a collaboration pinch FUJIFILM Biosciences. The collaboration will attraction connected optimizing a VSE formulation for FUJIFILM Biosciences BalanCD® HEK293 media to support world and commercialized AAV producers globally.

AAV vectors are a cornerstone of in vivo cistron transportation for cistron therapies, but they stay difficult and costly to manufacture astatine scale. As pipelines grow to much indications and broader diligent populations, importantly greater amounts of high-quality AAV are required, while nan request for commercially viable therapies places unit connected cost-of-goods. Current manufacturing methods and underlying economics are often not capable to meet this demand. By pairing high-performance FUJIFILM Biosciences BalanCD media pinch Virica's VSE enhancers, nan collaboration intends to present important AAV productivity gains and much robust, scalable processes.

To support FUJIFILM Biosciences' merchandise strategy, Virica will optimize VSE formulations and process parameters for AAV accumulation successful FUJIFILM Biosciences BalanCD HEK293 media pinch suspension HEK293 cells. This activity will leverage Virica's High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) frameworks, and analytical testing. FUJIFILM Biosciences will lend heavy expertise successful media and provender supplements and scale-up capabilities to nan collaborative project. The project, supported by NRC IRAP, intends to make VSE formulations tailored pinch nan FUJIFILM Biosciences BalanCD HEK293 system, enabling an off-the-shelf enhancer-media operation that extremity users tin adopt pinch minimal process changes.

We spot a beardown fresh betwixt our VSE exertion and FUJIFILM Biosciences BalanCD media portfolio, Following nan caller motorboat of our CellVantage-AAV off-the-shelf enhancer, our extremity is to supply an optimized formulation to present further AAV productivity gains specifically successful nan FUJIFILM Biosciences BalanCD HEK293 system."

Dr. Jean-Simon Diallo, Scientific Co-founder and Chief Executive Officer, Virica Biotech

"We stay committed to offering integrated solutions that harvester high-performance media pinch enabling technologies," said Yutaka Yamaguchi, Chairman and Chief Executive Officer astatine FUJIFILM Biosciences. "Optimizing Virica's VSE-based enhancers pinch our FUJIFILM Biosciences BalanCD HEK293 strategy will thief america present an easy-to-implement action for improving AAV yields and supporting businesslike scale-up for our customers."